Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

NCT06797362 is registered in ClinicalTrials.gov with Nuvalent Inc. as lead sponsor.

NCT NCT06797362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06797362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Lead sponsor
Nuvalent Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, ros1-positive non-small cell lung cancer (nsclc)